INTRODUCTION
Sézary syndrome (SS) is considered the leukemic variant of mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma (CTCL). SS is classically manifested by the triad of pruritic erythroderma, generalized lymphadenopathy, and the presence of atypical large circulating mononuclear cells with convoluted nuclei (Sézary cells) (Olsen et al., 2011) . The prevalence of SS is approximately 0.3 cases per 100,000 people, and it accounts for less than 5% of all CTCLs. SS is observed almost exclusively in adults and elderly patients and is more prevalent in men than women, with a ratio of 2:1. It is an aggressive disease with a poor outcome. (The 5-year overall survival rate is between 30 and 40%). SS may develop de novo or in a patient with a previous diagnosis of MF. The disease generally is much more aggressive, progresses faster, and is more resistant to treatment than classical MF (Agar et al., 2010; Scarisbrick et al., 2015) . The genetic etiology of CTCL is largely unknown. Cytogenetic studies of SS have identified abnormalities on chromosomes 1p, 2p, 6q, 9, 10q, 13q, 17p, and 21 (Brito-Babapulle et al., 1997; Espinet et al., 2004; Johnson et al., 1985; Karenko et al., 1997; Limon et al., 1995; Solé et al., 1994) .
Next-generation sequencing approaches have revolutionized cancer genomics research with successful application to the study of many hematological cancers, including chronic lymphocytic leukemia (Puente et al., 2011; Quesada et al., 2012) , acute myeloid leukemia (Ding et al., 2012; Ley et al., 2008; Mardis et al., 2009) , diffuse large B-cell lymphoma (Ngo et al., 2011; Pasqualucci et al., 2011) , and Burkitt's lymphoma (Schmitz et al., 2012) . Recently, several studies looking at the mutational landscape of CTCL and SS identifying key genomic alterations have been reported (Choi et al., 2015; da Silva Almeida et al., 2015; Kiel et al., 2015; McGirt et al., 2015; Pérez et al., 2015; Ungewickell et al., 2015; Vaque et al., 2014; Wang et al., 2015) . Genes involved in T-cell activation and apoptosis, NF-kB signaling, chromatin remodeling, and DNA damage response have been found to be altered (Choi et al., 2015) . In addition, signaling pathways including Jak/signal transducer and activator of transcription (STAT) signaling and cell-cycle checkpoint have been shown to be involved in the pathogenesis of CTCL (Pérez et al., 2015; Wang et al., 2015) .
Fusion genes play an important role in tumor development because they might result in disruption of either tumor suppressor genes or activation of proto-oncogenes. Targeting small molecules to these fusion gene products could be crucial in the treatment of cancer. A highly expressed gene fusion between CTLA4 and CD28 was discovered in SS in two independent studies (Sekulic et al., 2015; Ungewickell et al., 2015) . Here, we have applied whole-exome and RNA sequencing approaches to 15 erythrodermic patients with circulating Sézary cells, 14 of them fulfilling the diagnostic criteria of SS patients, to study the genomic landscape of SS. We have evaluated the somatic mutation spectrum in these samples to identify putative driver mutations in genes involved in the progression of the disease. In addition, we have analyzed their transcriptome to search for fusion genes.
RESULTS AND DISCUSSION

Spectrum of somatic point mutations
We observed a median of 54 somatic point mutations (range, 4e88) in SS patients ( Figure 1a and see Supplementary Table S1 online). Two patients (SS06 and SS09) had a relatively low number of somatic point mutations compared with the other patients. One of these (patient SS06) turned out to have a diagnosis of pre-SS. Of all the mutations, 68% of them were C>T transitions (Figure 1b) . A higher percentage of C>T transition mutations has also been reported in previous studies involving CTCL, and the possibility of the contribution of UV exposure to MF has been discussed (Choi et al., 2015; McGirt et al., 2015) .
We have identified four genes with recurrent somatic mutations in this cohort of SS patients: TP53, ITPR1, DSC1, and PKHD1L1 (Figure 2 ). Somatic mutations in TP53 were found in three patients, including one stop-gain mutation. Recurrent mutations in TP53 have been reported in patients with CTCL (Choi et al., 2015) , SS, and MF (Ungewickell et al., 2015) , but recurrent mutations in ITPR1, DSC1, and PKHD1L1, to our knowledge, have not been previously reported in studies of SS. We found damaging somatic mutations in ITPR1 in two SS patients. A common variant in the gene ITPR1 has been shown to be associated with susceptibility to breast cancer (Michailidou et al., 2013) . ITPR1 mediates calcium release from the endoplasmic reticulum, and one of the predicted functional partners of ITPR1 is BCL2, which suppresses apoptosis in different cell systems, including lymphohematopoietic and neural cells (Snel et al., 2000; STRING: protein-protein Interaction Networks, 2000) . The other gene in which we found highly damaging somatic mutations in two patients was DSC1, which has been shown to be associated with different cancer types, including colorectal cancer and liver metastasis (Khan et al., 2006; Schü le et al., 2014) . Lastly, somatic mutations in two SS patients were observed in PKHD1L1, including one missense and one stop-gain mutation. PKHD1L1 is a homologue of the autosomal recessive polycystic kidney disease gene, and it encodes a receptor with inducible T-lymphocyte expression, suggesting a role in cellular immunity (Hogan et al., 2003) . Somatic mutations in PKHD1L1 have been implicated in gastric cancer in one study .
We identified several genes with singleton somatic mutations in our patients, including PLCG1, STAT5B, GLI3, CARD11, NAV3, RIPK2, IL6, RAG2, and ITPR2 (see Supplementary Figure S1 online). Some of these genes have been previously shown to be associated with CTCL, including PLCG1, STAT5B, GLI3, CARD11, and NAV3 (Choi et al., 2015; da Silva Almeida et al., 2015; Karenko et al., 2005; Kiel et al., 2015; Ungewickell et al., 2015; Vaque et al., 2014; Wang et al., 2015) . We found the same somatic mutation in PLCG1 (c.1034T>C, S345F) as reported in the study of Vaque et al. (2014) and an N642H mutation in the structurally conserved Src homology 2 (SH2) domain of the STAT5B gene (Choi et al., 2015) . The oncogenic potential of the N642H mutation in STAT5B was shown earlier in pediatric T-cell acute lymphoblastic leukemia (Bandapalli et al., 2014; Kontro et al., 2014) , in adult T-cell acute lymphoblastic leukemia (Ma et al., 2015) , and in large granular lymphocytic leukemia (Rajala et al., 2013) . We observed a somatic missense mutation in CARD11 and a stop-gain mutation (R792X) in GLI3 in our dataset. The caspase recruitment domains (CARDs) of the CARD11 gene are shown to interact with the CARD domain of BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-kB activation (Bertin et al., 2001) . CARD11 is involved in the T-cell receptor signaling pathway, making it a potential candidate gene for SS pathogenesis. We observed a somatic point mutation (Chr12:78569178, G>A) in NAV3 in one of our SS patients. A previous study identified NAV3 as a putative tumor suppressor in CTCL, because 50e85% of CTCL patients showed a deletion or translocation affecting NAV3 (Karenko et al., 2005) . However, a later study could not confirm these observations (Marty et al., 2008) . These results were also not confirmed with our array comparative genomic hybridization study on tumor stage MF (Salgado et al., 2010) . Somatic mutations in NAV3 have been reported in other cancer types including breast, colorectal, melanoma, and pancreatic carcinomas (Bleeker et al., 2009; Wood et al., 2007) . According to the Catalogue of Somatic Mutations in Cancer (i.e., COSMIC), mouse insertional mutagenesis experiments support NAV3 as a cancer driver gene. To our knowledge, somatic point mutations in NAV3 have not been reported previously in CTCL studies. NAV3 may have a role in the regulation of IL2 production by T cells and has also been predicted as a high-confidence cancer driver using the IntOGen mutation analysis pipeline (Gonzalez-Perez et al., 2013) . The other genes with singleton somatic point mutations are IL6, RIPK2, RAG2, and ITPR2. IL6 and RIPK2 are key components of regulation of CD4 þ cells and activation/ differentiation of alpha-beta T cells involved in immune response. We also observed a somatic missense mutation affecting the plant homeodomain domain of RAG2 in one SS patient. The plant homeodomain domain is found at the C-terminus of the recombination activating gene (RAG) 2 protein, which modulates its recombination activity (Elkin et al., 2005) . This protein was shown to be involved in the process of T-cell differentiation in the thymus, and Choi et al. (2015) reported enrichment of RAG heptamers in CTCL breakpoints. It is important to note that somatic mutations in some genes, including NAV3 (Chr12:78569178, G>A), IL6 (Chr7:22767146, G>A), and ITPR2 (Chr12:26553068, G>A), were detected only using the Agilent SureSelect Target Enrichment Exome (Agilent Technologies, Santa Clara, California, USA) but were missed from the experiments using the Nextera Capture Exome (Illumina, San Diego, California, USA). This was probably not because of different probe coverage between the two capture kits but because the Mutect application was unable to detect these mutations from the Nextera experiments. We used Sanger sequencing to validate these mutations by ruling out false-positive results.
We do not see a similar rate of recurrence for some of the mutations as has been observed in earlier studies, for example, for PLCG1 and CARD11. This is mainly because of the small sample size of our dataset compared with those of other studies (Kiel et al., 2015; Wang et al., 2015) . PLCG1 was first found to be mutated in 9% of the patients with SS (Vaque et al., 2014) . In one of the largest studies on SS, the frequency of PLCG1 mutations was 14% (5 of 37 patients) in the original cohort, and it increased to 21% (14 of 68 patients) in the extension cohort . Some previous studies have investigated CTCL, which includes patients with both MF and SS. Therefore, both the diagnostic heterogeneity among studies and the clinical heterogeneity of SS per se could contribute to the fact that only some genetic alterations are common between the different studies performed. (Cerami et al., 2012; Gao et al., 2013) .
Landscape of somatic duplications
We found 61 somatic duplications across 10 patients, with an average of six duplications per patient (see Supplementary  Table S2 2p15, 3p26.3, 5q23.1, 6p12.3, 7p15.2, 7p12.3ep13, 7q34, 10p12.1, 10q21.3, 12q24.31, 13q21.33, 16p11.2, 16p13.3, 19p13.2, and 19q13.32) encompassed genes that play a role in tumorigenesis or have been found to be involved in several different human cancer types.
We found a 6-kilobase (kb) duplication involving several exons of ANKRD26 on 10p12.1, encoding a protein containing N-terminal ankyrin repeats, which function in protein-protein interactions. Mutations in this protein are associated with autosomal-dominant thrombocytopenia and myeloid malignancies (Noris et al., 2013) . In addition, the The colored lines in the innermost circle show fusion transcripts. This figure is generated using Circos software package (Krzywinski et al., 2009). 32-kb duplication on chromosome band 16p11.2 involves part of the tumor suppressor BCL7C gene (Uehara et al., 2015) . Another duplication of interest is 29-kb duplication on chromosome band 6p21.1 that encompasses some exons of CRIP3, which is involved in the process of T-cell proliferation. In addition, we observed a 463-kb duplication of chromosome bands 7p12.3e13, encompassing three genes, including TBRG4 and RAMP3. TBRG4 encodes transforming growth factor-beta regulator 4, and RAMP3 encodes a protein involved in the G-protein coupled receptor signaling pathway.
Landscape of somatic deletions
A total of 60 somatic deletions were observed across 10 SS samples, with a median of 5 deletions per sample (see Supplementary Table S3 online and Figure 3) . Several large deletions (>5 Mb) were shared by patients: a 55e110-Mb deletion on 10p11.1eq26.3 in two patients, a 17-Mb deletion on 11q23.3eq25 in two patients, a 15e25-Mb deletion on 17p12ep13.3 in six patients (encompassing several genes including TP53), and a 9-Mb deletion on 19p13.2ep13.3 in two patients.
We observed a somatic deletion of approximately 600 kb on 14q11.2 in patients SS02 and SS07 affecting the DAD1 gene. The loss of DAD1 protein has been shown to trigger apoptosis (Yulug et al., 1995) , and DAD1 protein overexpression is found to be associated with small bowel carcinoid tumors (Kulke et al., 2008) . Another interesting example is a 100-kb deletion on 3q23 encompassing several exons of RASA2 in patient SS01. RASA2 encodes a protooncogene that plays an important role in the mitogenactivated protein kinase signaling pathway that is involved in various cellular functions, including cell proliferation, differentiation, and migration. In the same patient (SS01), we observed another interesting deletion (210 kb) on 3q13.11 encompassing the CBLB gene (da Silva Almeida et al., 2015) . CBLB encodes a proto-oncogene involved in T-cell activation, negative regulation of the T-cell receptor signaling pathway, and negative regulation of alpha-beta T-cell proliferation (Elly et al., 1999) . In activated T cells, CBLB inhibits PLCG1 activation and calcium mobilization upon restimulation (Yasuda et al., 2002) . The entire chromosome 3 was alternated by duplications and deletions in patient SS01 and was possibly affected by chromothripsis-like rearrangements.
In our patients, chromosome 17 was largely affected by genomic changes, including somatic point mutations and copy number variations. Of special interest is the gene TP53, which was affected in 58% of patients (7 of 12), either by somatic point mutations or by somatic deletion with a somatic copy number variation (CNV)/somatic single nucleotide variant (SNV) ratio of 2:1. Although a previous study reported 92.5% of patients with CTCLs (n ¼ 40) with a somatic CNV:SNV ratio of 5.1:1 (Choi et al., 2015) , the difference is likely due to the low number of samples (n ¼ 12) in our study on which we have exome sequencing data available. Somatic point mutations in the TP53 gene were seen in three patients-SS03, SS10, and SS12-whereas large deletions on 17p involving the TP53 gene were detected in six patients, including SS01, SS02, SS03, SS08, SS10, and SS11. We identified two patients with a double-knockout TP53 clone. Patient SS03 harbors a 25-Mb deletion on 17p encompassing TP53 and present in almost all the cells of the patient. This patient also has a subclonal mutation in TP53. It is likely that, because of the strong effect of complete loss of functional TP53, this clone would be positively selected and, over the course of time, could dominate the tumor population. Patient SS10 has both a stop-gain mutation in TP53 and a 15-Mb deletion on 17p encompassing TP53 and is clonalthat is, affecting all the cells-resulting in no functional copy of the TP53 gene in this patient. These two patients were diagnosed at a relatively early age compared with the rest of the patients, but statistics are insufficient to claim that this is because of the presence of a homozygous loss of TP53.
Fusion events
A total of 86 potential fusion events were observed across 10 SS samples (see Supplementary Table S4 online). Fusion RNAs including TYK2-UPF1, COL25A1-NFKB2, FASN-SGMS1, SGMS1-ZEB1, SPATA21-RASA2, PITRM1-HK1, and BCR-NDUFAF6 were successfully validated. Complex chromosomal rearrangements were observed in two of our patients (SS04 and SS13), as was evident with the fusion events identified in these patients (see Supplementary Figure S2 online). Patient SS04 had fusion events FASN-SGMS1 and SGMS1-ZEB1. The protein of fatty acid synthase (FASN), in some cancer cell lines, gets fused with estrogen receptor-a, in which the N-terminus of fatty acid synthase is fused in-frame with the C-terminus of estrogen receptor-a (Entrez gene, 2008). FASN is involved in several cancer types, including hepatocellular carcinoma, colorectal cancer, and prostate cancer (Hao et al., 2014; Madigan et al., 2014; Zaytseva et al., 2014) . The other partner of the fusion gene FASN-SGMS1 is sphingomyelin synthase 1 (SGMS1), the activity of which is regulated by the breakpoint cluster region-ABL proto-oncogene, non-receptor tyrosine kinase oncogene. The partner ZEB1 of the SGMS1-ZEB1 fusion gene encodes a zinc finger transcription factor and acts as a transcriptional repressor of IL2. The ZEB1 gene is involved in the process of regulation of T-cell differentiation in the thymus and has been strongly implicated in the pathogenesis of CTCL and SS (Choi et al., 2015; Kiel et al., 2015; McGirt et al., 2015; Wang et al., 2015) . Patient SS13 had both TYK2-UPF1 and COL25A1-NFKB2 fusion events. The TYK2 gene was shown to be essential for the differentiation and function of different immune cells, including natural killer cells, B cells, and T-helper cells (Liang et al., 2014) . The gene NFKB2 is a pleiotropic transcription factor that is involved in several pathways including NF-kB signaling, which regulates the transcription of many genes involved in cancer initiation and progression. NFKB2 was shown to be disrupted in earlier CTCL studies (Choi et al., 2015; Ungewickell et al., 2015) , and the effectiveness of using NF-kB inhibitors such as bortezomib has been discussed in a phase II trial (Zinzani et al., 2007) . We observed the fusion gene SPATA21-RASA2 in patient SS01, in whom we also observed the 100-kb somatic deletion on 3q23 encompassing almost all exons of RASA2, indicating the mechanism behind formation of this fusion gene. The PITRM1-HK1 fusion event was found in patient SS05. The elevated level of hexokinase 1 has been shown to promote tumor cells to avoid apoptosis, thereby allowing cell proliferation to continue (Azoulay-Zohar et al., 2004) . In patient SS15, we observed a fusion gene involving BCR-NDUFAF6. A BCR-ABL fusion transcript involving exon 8 and exon 4, respectively, has been reported in a SS patient (Callet-Bauchu et al., 2007) . Table 1 summarizes the key somatic genomic changes across 15 patients.
In patient SS09, we did not observe any somatic point mutation or copy number variation that could be involved in 
X denotes somatic single nucleotide variant; X* denotes somatic stop-gain single nucleotide variant; þ denotes somatic duplication; e denotes somatic deletion; ǂ denotes fusion event; F denotes germline splice-site mutation in the ATM.
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The genes and the genetic alterations that, to the best of our knowledge, have not been reported in previous studies of Sézary syndrome are highlighted in bold. It is important to mention that translocations/deletions in NAV3 have been reported in an earlier study (Karenko et al., 2005) . However, somatic mutations have not been reported in NAV3 in cutaneous T-cell lymphoma. In addition, somatic mutations in ATM have been previously reported. We have not seen studies reporting germline mutations in ATM in Sézary syndrome earlier.
the pathogenesis of disease in this patient. Although the focus of this study was primarily on somatic mutations, we found a germline splice-site mutation (NM_000051:exon16:c.2377-2A>G) in the ATM gene in this patient. The variant has an allele fraction of 0.567, as expected for a heterozygous germline mutation present in all cells of the patient in a diploid locus. This splice-site mutation is affecting the FAT (FRAP, ATM, TRAPP) domain of ATM (ATM serine/threonine kinase). Although the function of this domain is not clear, it has been suggested that the FAT domain interacts with the kinase domain to stabilize the carboxy-terminal end of the protein (Bakkenist and Kastan, 2003) . ATM is an important mediator of the DNA damage response pathway. However, in the absence of supporting biological data, we cannot conclude that this particular germline mutation is involved in disease susceptibility in this patient. Our study presents a complex genomic landscape of SS with several somatic point mutations, copy number variations, and fusion events that could contribute to the pathogenesis of SS. Based on the evidence from our studies and previous studies, it is likely that genes TP53, ITPR1, PLCG1, CARD11, STAT5B, RASA2, CBLB, DAD1, TYK2, FASN, SGMS1, NFKB2, ZEB1, HK1, and BCR could be involved in the pathogenesis of the disease. A number of somatic deletions and duplications identified in this study were shared among patients, indicating that chromosomal instability is a feature of this type of lymphoma. Finally, the fusion genes identified in this study could be targeted for therapeutic implications.
MATERIALS AND METHODS
Sample collection
Fifteen erythrodermic patients presenting with circulation of atypical cerebriform lymphoid cells (Sézary cells) were selected for study. Fourteen patients fulfilled the diagnostic criteria for SS with B2 level of blood involvement proposed by the International Society for Cutaneous Lymphomas (i.e., ISCL) and the European Organization for Research and Treatment of Cancer (i.e., EORTC) (Olsen et al., 2011) , and one patient with the de novo erythroderma had less than 1,000 circulating Sézary cells/mm 3 (B1 level of blood involvement) (see Supplementary Table S5 The participation of human subjects in this study was approved by the institutional review board of each hospital, and written informed consent was obtained following Helsinki protocols. Peripheral blood samples were collected for each patient, and CD4 þ T lymphocytes were isolated by using magnetic beads (Miltenyi Biotec, Auburn, California, USA). Granulocytes were isolated by dextran sedimentation to obtain matched normal cells. DNA was extracted using the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). RNA was extracted from matched normal and tumor materials for a total of 10 SS samples using the miRNeasy kit (Qiagen). RNA sequencing was performed on these samples. However exome as well as RNA sequencing data were obtained for only seven of them, as detailed in Supplementary Table S6 online.
Whole-exome sequencing DNA libraries for 12 matched tumor (CD4 þ ) and normal (granulocyte) cells from SS patients were prepared using the Illumina Nextera DNA Sample Prep kit (Illumina, San Diego, California, USA). The exomes were captured using Nextera rapid capture exome (37 Mb) and sequenced on the Illumina HiSeq 2000 platform as a 100-base pair paired-end run. In addition, genomic DNA from six samples was also captured using the Agilent SureSelect Human All Exon v4 þUTR kit (71 Mb) (Agilent Technologies, Santa Clara, California, USA). The library enriched for target regions was sequenced on the Illumina HiSeq 2000 platform as a 100-base pair paired-end run. The average depth of coverage for the samples captured using the Nextera capture kit was 37Â (range ¼ 25e48Â), whereas for the samples captured using the Agilent SureSelect capture kit it was 31Â (range ¼ 23e49Â) of coverage (see Supplementary Table S7 online).
Alignment and SNV calling
The reads generated from the sequencer were aligned to the human genome reference sequence (hg19) using Burrows-Wheeler alignment (BWA-maximal exact match algorithm) (Li and Durbin, 2009 ). Any duplicate reads were flagged using the MarkDuplicates algorithm from Picard (http://broadinstitute.github.io/picard/). Base quality recalibrations were performed using The Genome Analysis Toolkit haplotype caller (DePristo et al., 2011) . Somatic SNVs were detected using MuTect (Cibulskis et al., 2013) and were filtered following the standard recommendation to obtain a set of confident calls. The somatic SNVs obtained using MuTect were further annotated, providing information about the impact of the mutation, the damage potential, and the allele frequency of the somatic SNV in the 1000 Genome (1000 Genomes Project Consortium, 2010) and the Exome Variant Server database (National Heart, Lung, and Blood Institute Exome Sequencing Project, found at http://evs.gs. washington.edu/EVS/). A subset of candidate somatic mutations was validated by Sanger sequencing in CD4 þ and granulocyte DNA as control. We analyzed the exome sequencing data for somatic point mutations from both Agilent and Nextera capture kits. For simplification, all the statistics presented in this study are from the Nextera kit, because it was used for all the DNA samples.
Identification of somatic CNVs
Somatic CNVs were identified using an in-house algorithm ClinCNV (manuscript in preparation). ClinCNV computes coverage within samples and across a set of samples and infers CNVs by referring each sample to the computed average and to its matched pair (if available).
Further support for CNV is obtained by calculating changes in allele frequency in tumor samples versus matched normal control samples. To define putative deletions and duplications, we established the cutoffs for deletions and duplications at a tumor-to-normal ratio of less than 0.7 and greater than 1.3, respectively, with greater than 77% significant probes in the region. This threshold was relaxed for only one deletion on chromosome 17 in three patients (SS03, SS10, SS11) because the deletion was present in high confidence in three of the other patients, had been reported earlier in literature (Caprini et al., 2009; Vermeer et al., 2008) , and was likely to be a true positive.
ClinCNV computes the cancer cell fraction for each CNV using an analytical formula published previously (Bassaganyas et al., 2013) .
RNA sequencing and fusion transcript discovery
Stranded messenger RNA libraries for 10 tumor (CD4 þ ) samples were generated by polyA selection using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina library preparation kit (New England Biolabs Inc., Ipswich, MA), starting from 700 ng of total RNA. Libraries were sequenced on three lanes of the Illumina Hiseq2500 sequencing platform as a 125-base pair paired-end run. Quality check of the data was performed using FastQC (Babraham Institute, Babraham, Cambridge, United Kingdom; available at http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The sequencing data for messenger RNA was aligned to the reference genome using STAR (Spliced Transcripts Alignment to Reference), applying parameters optimized for the detection of chimeric reads (Dobin et al., 2013) . The resulting potential fusion transcripts were further evaluated both manually and using the R Bioconductor package Chimera (version 1.12.0) (Beccuti et al., 2014) . A minimum of 10 supporting (spanning) reads was used as a threshold for fusion transcripts, and the sequence around donor and acceptor sites of potential chimeric reads was manually evaluated to discard potential false positives. We visually inspected Integrated Genome Viewer (Robinson et al., 2011) and RNA expression data and selected some fusion events for validation by real-time PCR.
Accession codes
The exome and RNA sequencing data have been deposited at the European Genome-Phenome Archive (available at http://www.ebi. ac.uk/ega/), which is hosted at the European Bioinformatics institute under accession number EGAS00001001706. 
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